Anika Therapeutics, Inc. (NASDAQ:ANIK)
| Market Cap | 261.37M+111.4% |
| Revenue (ttm) | 120.65M+31.4% |
| Net Income | -3.78M+93.8% |
| EPS | -0.27+93.5% |
| Shares Out | 13.38M |
| PE Ratio | n/a |
| Forward PE | 20.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 182,653 |
| Open | 19.16 |
| Previous Close | 19.12 |
| Day's Range | 18.11 - 19.62 |
| 52-Week Range | 8.67 - 22.88 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 21.00(+7.53%) |
| Earnings Date | Nov 4, 2026 |
Anika Therapeutics, Inc. has a live Insider Score.
Scored on 2 qualifying trades from 1 insider in the last 90 days.
About ANIK
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ANIK stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ANIK holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ANIK's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ANIK Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ANIK Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Income (loss) from continuing operations | $3.31M | 49.47% |
| Loss from operations | $2.95M | 44.16% |
| Interest and other income, net | $426.00K | 6.37% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ANIK patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ANIK from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ANIK
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $8.30M |
| IWMiShares Russell 2000 ETF | $5.80M |
| VXFVanguard Extended Market ETF | $3.26M |
| DFSVU.S. Small Cap Value Portfolio ETF Class Shares | $2.91M |
| FSMDFidelity Small-Mid Multifactor ETF | $2.04M |
| DFASDimensional - US Small Cap ETF | $1.96M |
Estimated from each fund’s disclosed top holdings × AUM
ANIK Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ANIK’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score